We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+1.55%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$1.06T
AUM Growth
-$16.9B
Cap. Flow
-$16.2B
Cap. Flow %
-1.53%
Top 10 Hldgs %
26.1%
Holding
3,048
New
131
Increased
1,029
Reduced
1,524
Closed
112

Top Buys

Rank Stock Value
1
XYZ
Block Inc
XYZ
+$2.39B
2
CVNA icon
Carvana
CVNA
+$1.82B
3
MSFT icon
Microsoft
MSFT
+$1.5B
4
DIS icon
Walt Disney
DIS
+$1.25B
5
SPOT icon
Spotify
SPOT
+$1.05B

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$2.65B
2
INTU icon
Intuit
INTU
+$2.08B
3
MTCH icon
Match Group
MTCH
+$1.87B
4
CRM icon
Salesforce
CRM
+$1.76B
5
META icon
Meta Platforms (Facebook)
META
+$1.61B

Sector Composition

Rank Sector Weight
1 Technology 25.08%
2 Healthcare 16.24%
3 Consumer Discretionary 15.33%
4 Communication Services 13.82%
5 Financials 12.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IMDX
2826
Insight Molecular Diagnostics
IMDX
$137M
$104K ﹤0.01%
1,454
+10
+0.7% +$919
PGEN icon
2827
Precigen
PGEN
$2.38B
$104K ﹤0.01%
20,766
LMACU
2828
DELISTED
Liberty Media Acquisition Corporation Unit
LMACU
$104K ﹤0.01%
10,040
PBYI icon
2829
Puma Biotechnology
PBYI
$457M
$103K ﹤0.01%
14,668
AP icon
2830
Ampco-Pittsburgh
AP
$193M
$102K ﹤0.01%
21,600
DCH
2831
Dauch Corp
DCH
$1.58B
$102K ﹤0.01%
11,555
+700
+6% +$6.42K
ARKO icon
2832
ARKO Corp
ARKO
$507M
$101K ﹤0.01%
+10,040
New +$90.4K
CNVS icon
2833
Cineverse
CNVS
$69.7M
$101K ﹤0.01%
2,005
TONX
2834
TON Strategy Co
TONX
$151M
$101K ﹤0.01%
+7
New +$119K
CTAQ
2835
DELISTED
Carney Technology Acquisition Corp. II Class A Common Stock
CTAQ
$101K ﹤0.01%
10,377
LCI
2836
DELISTED
Lannett Company, Inc.
LCI
$101K ﹤0.01%
8,400
ALDX icon
2837
Aldeyra Therapeutics
ALDX
$93.5M
$98K ﹤0.01%
11,164
-100
-0.9% -$918
KODK icon
2838
Kodak
KODK
$980M
$98K ﹤0.01%
14,374
+400
+3% +$2.92K
NERV icon
2839
Minerva Neurosciences
NERV
$193M
$98K ﹤0.01%
7,038
SLS icon
2840
SELLAS Life Sciences
SLS
$2.44B
$98K ﹤0.01%
10,700
-4,800
-31% -$44.5K
TXMD icon
2841
TherapeuticsMD
TXMD
$24.2M
$98K ﹤0.01%
2,644
-367,221
-99% -$16.3M
HROW icon
2842
Harrow
HROW
$1.49B
$97K ﹤0.01%
10,700
CTIC
2843
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$96K ﹤0.01%
32,700
CBUS icon
2844
Cibus
CBUS
$147M
$95K ﹤0.01%
562
EPM icon
2845
Evolution Petroleum
EPM
$135M
$95K ﹤0.01%
+16,800
New +$75K
FRO icon
2846
Frontline
FRO
$9.06B
$95K ﹤0.01%
+10,131
New +$80.4K
STXS icon
2847
Stereotaxis
STXS
$137M
$95K ﹤0.01%
17,655
-300
-2% -$2.26K
ATOS icon
2848
Atossa Therapeutics
ATOS
$24.2M
$90K ﹤0.01%
1,836
+180
+11% +$10.5K
AXDX
2849
DELISTED
Accelerate Diagnostics
AXDX
$88K ﹤0.01%
1,515
+30
+2% +$1.96K
TOON icon
2850
Kartoon Studios
TOON
$38.5M
$88K ﹤0.01%
6,495
+1,590
+32% +$24.7K

Similar funds

T. Rowe Price Associates's Q3 2021 Portfolio in Review

As of Q3 2021, T. Rowe Price Associates held 3,048 positions worth $1.06T, down 1.6% from $1.08T the previous quarter. Its ten largest holdings account for 26% of the portfolio.

T. Rowe Price Associates's Q3 2021 filing shows 131 new, 1,029 increased, 1,524 reduced and 112 closed positions. Its largest new stake was Warby Parker: 17,643,113 shares worth $936M. The largest sale was Visa, an estimated $2.65B.

By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q3 2021 buy was Warby Parker: 17,643,113 shares worth $936M.
  • T. Rowe Price Associates added most to Block Inc in Q3 2021, an estimated $2.39B increase.
  • T. Rowe Price Associates's biggest Q3 2021 reduction was Visa, cutting an estimated $2.65B.
  • T. Rowe Price Associates fully exited Maxim Integrated Products in Q3 2021, selling an estimated $394M.
  • T. Rowe Price Associates's ten largest holdings make up 26% of its $1.06T portfolio in Q3 2021.
  • T. Rowe Price Associates opened 131 new positions and closed 112 in Q3 2021.
  • T. Rowe Price Associates's portfolio value fell 1.6% quarter-over-quarter to $1.06T.

Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.